Logo image of 1BMY.MI

BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:1BMY - US1101221083 - Common Stock

39.635 EUR
+1.23 (+3.22%)
Last: 11/20/2025, 7:00:00 PM
Fundamental Rating

6

Overall 1BMY gets a fundamental rating of 6 out of 10. We evaluated 1BMY against 55 industry peers in the Pharmaceuticals industry. 1BMY has an average financial health and profitability rating. 1BMY may be a bit undervalued, certainly considering the very reasonable score on growth 1BMY also has an excellent dividend rating. These ratings would make 1BMY suitable for value and dividend investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

1BMY had positive earnings in the past year.
In the past year 1BMY had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1BMY reported negative net income in multiple years.
Each year in the past 5 years 1BMY had a positive operating cash flow.
1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCF1BMY.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B

1.2 Ratios

The Return On Assets of 1BMY (6.23%) is comparable to the rest of the industry.
With a decent Return On Equity value of 32.55%, 1BMY is doing good in the industry, outperforming 80.00% of the companies in the same industry.
1BMY has a better Return On Invested Capital (17.49%) than 81.82% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1BMY is below the industry average of 13.92%.
The 3 year average ROIC (11.67%) for 1BMY is below the current ROIC(17.49%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROIC 17.49%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
1BMY.MI Yearly ROA, ROE, ROIC1BMY.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

With a Profit Margin value of 12.57%, 1BMY perfoms like the industry average, outperforming 52.73% of the companies in the same industry.
Looking at the Operating Margin, with a value of 33.51%, 1BMY belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
1BMY's Operating Margin has declined in the last couple of years.
The Gross Margin of 1BMY (73.15%) is comparable to the rest of the industry.
1BMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
1BMY.MI Yearly Profit, Operating, Gross Margins1BMY.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1BMY is creating value.
The number of shares outstanding for 1BMY has been reduced compared to 1 year ago.
The number of shares outstanding for 1BMY has been reduced compared to 5 years ago.
The debt/assets ratio for 1BMY is higher compared to a year ago.
1BMY.MI Yearly Shares Outstanding1BMY.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B
1BMY.MI Yearly Total Debt VS Total Assets1BMY.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

1BMY has an Altman-Z score of 2.10. This is not the best score and indicates that 1BMY is in the grey zone with still only limited risk for bankruptcy at the moment.
1BMY has a worse Altman-Z score (2.10) than 61.82% of its industry peers.
The Debt to FCF ratio of 1BMY is 3.20, which is a good value as it means it would take 1BMY, 3.20 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.20, 1BMY is in the better half of the industry, outperforming 61.82% of the companies in the same industry.
A Debt/Equity ratio of 2.41 is on the high side and indicates that 1BMY has dependencies on debt financing.
The Debt to Equity ratio of 1BMY (2.41) is worse than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Altman-Z 2.1
ROIC/WACC2.14
WACC8.19%
1BMY.MI Yearly LT Debt VS Equity VS FCF1BMY.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.3 Liquidity

A Current Ratio of 1.27 indicates that 1BMY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.27, 1BMY is doing worse than 65.45% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that 1BMY should not have too much problems paying its short term obligations.
The Quick ratio of 1BMY (1.17) is better than 65.45% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.17
1BMY.MI Yearly Current Assets VS Current Liabilites1BMY.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 460.68% over the past year.
Measured over the past years, 1BMY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.57% on average per year.
The Revenue has been growing slightly by 1.26% in the past year.
The Revenue has been growing by 13.06% on average over the past years. This is quite good.
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%

3.2 Future

Based on estimates for the next years, 1BMY will show a very strong growth in Earnings Per Share. The EPS will grow by 35.26% on average per year.
1BMY is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.97% yearly.
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-4.97%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1BMY.MI Yearly Revenue VS Estimates1BMY.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B
1BMY.MI Yearly EPS VS Estimates1BMY.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

9

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 6.99, the valuation of 1BMY can be described as very cheap.
1BMY's Price/Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 94.55% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.11. 1BMY is valued rather cheaply when compared to this.
Based on the Price/Forward Earnings ratio of 7.53, the valuation of 1BMY can be described as very cheap.
1BMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BMY is cheaper than 90.91% of the companies in the same industry.
1BMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.21.
Industry RankSector Rank
PE 6.99
Fwd PE 7.53
1BMY.MI Price Earnings VS Forward Price Earnings1BMY.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1BMY is valued cheaply inside the industry as 94.55% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1BMY is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.1
EV/EBITDA 5.94
1BMY.MI Per share data1BMY.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1BMY's earnings are expected to grow with 73.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y131.12%
EPS Next 3Y73.23%

8

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.04%, 1BMY is a good candidate for dividend investing.
1BMY's Dividend Yield is rather good when compared to the industry average which is at 2.86. 1BMY pays more dividend than 90.91% of the companies in the same industry.
1BMY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.32.
Industry RankSector Rank
Dividend Yield 5.04%

5.2 History

On average, the dividend of 1BMY grows each year by 11.67%, which is quite nice.
Dividend Growth(5Y)11.67%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

1BMY pays out 82.81% of its income as dividend. This is not a sustainable payout ratio.
1BMY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP82.81%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
1BMY.MI Yearly Income VS Free CF VS Dividend1BMY.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B
1BMY.MI Dividend Payout.1BMY.MI Dividend Payout, showing the Payout Ratio.1BMY.MI Dividend Payout.PayoutRetained Earnings

BRISTOL-MYERS SQUIBB CO

BIT:1BMY (11/20/2025, 7:00:00 PM)

39.635

+1.23 (+3.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-05 2026-02-05/amc
Inst Owners82.84%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap80.69B
Revenue(TTM)48.03B
Net Income(TTM)6.04B
Analysts67.88
Price Target47.22 (19.14%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.04%
Yearly Dividend2.09
Dividend Growth(5Y)11.67%
DP82.81%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.98%
Min EPS beat(2)6.92%
Max EPS beat(2)35.04%
EPS beat(4)4
Avg EPS beat(4)18.72%
Min EPS beat(4)6.92%
Max EPS beat(4)35.04%
EPS beat(8)8
Avg EPS beat(8)16.52%
EPS beat(12)11
Avg EPS beat(12)11.66%
EPS beat(16)15
Avg EPS beat(16)10.13%
Revenue beat(2)2
Avg Revenue beat(2)4.61%
Min Revenue beat(2)2.43%
Max Revenue beat(2)6.79%
Revenue beat(4)4
Avg Revenue beat(4)4.63%
Min Revenue beat(4)2.43%
Max Revenue beat(4)6.79%
Revenue beat(8)8
Avg Revenue beat(8)3.95%
Revenue beat(12)9
Avg Revenue beat(12)1.94%
Revenue beat(16)11
Avg Revenue beat(16)1.64%
PT rev (1m)6.4%
PT rev (3m)2.19%
EPS NQ rev (1m)5.31%
EPS NQ rev (3m)4.49%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)-0.81%
Revenue NQ rev (1m)1.99%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)0.93%
Valuation
Industry RankSector Rank
PE 6.99
Fwd PE 7.53
P/S 1.94
P/FCF 6.1
P/OCF 5.61
P/B 5.03
P/tB N/A
EV/EBITDA 5.94
EPS(TTM)5.67
EY14.31%
EPS(NY)5.26
Fwd EY13.28%
FCF(TTM)6.5
FCFY16.4%
OCF(TTM)7.06
OCFY17.81%
SpS20.4
BVpS7.88
TBVpS-10.05
PEG (NY)0.01
PEG (5Y)N/A
Graham Number31.7
Profitability
Industry RankSector Rank
ROA 6.23%
ROE 32.55%
ROCE 23.41%
ROIC 17.49%
ROICexc 22.99%
ROICexgc 117.18%
OM 33.51%
PM (TTM) 12.57%
GM 73.15%
FCFM 31.86%
ROA(3y)1.77%
ROA(5y)0.82%
ROE(3y)-2.38%
ROE(5y)-2.3%
ROIC(3y)11.67%
ROIC(5y)9.83%
ROICexc(3y)13.73%
ROICexc(5y)11.71%
ROICexgc(3y)74.95%
ROICexgc(5y)76.74%
ROCE(3y)15.62%
ROCE(5y)13.15%
ROICexgc growth 3Y-16.88%
ROICexgc growth 5Y3.18%
ROICexc growth 3Y7.41%
ROICexc growth 5Y19.82%
OM growth 3Y-0.56%
OM growth 5Y-4.29%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.73%
GM growth 5Y1.42%
F-Score6
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 2.41
Debt/FCF 3.2
Debt/EBITDA 2.13
Cap/Depr 26.84%
Cap/Sales 2.75%
Interest Coverage 7.66
Cash Conversion 79.11%
Profit Quality 253.39%
Current Ratio 1.27
Quick Ratio 1.17
Altman-Z 2.1
F-Score6
WACC8.19%
ROIC/WACC2.14
Cap/Depr(3y)12.09%
Cap/Depr(5y)10.53%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)460.68%
EPS 3Y-46.63%
EPS 5Y-24.57%
EPS Q2Q%-9.44%
EPS Next Y472.54%
EPS Next 2Y131.12%
EPS Next 3Y73.23%
EPS Next 5Y35.26%
Revenue 1Y (TTM)1.26%
Revenue growth 3Y1.36%
Revenue growth 5Y13.06%
Sales Q2Q%2.77%
Revenue Next Year-0.35%
Revenue Next 2Y-4.29%
Revenue Next 3Y-3.28%
Revenue Next 5Y-4.97%
EBIT growth 1Y44.7%
EBIT growth 3Y0.79%
EBIT growth 5Y8.21%
EBIT Next Year263.82%
EBIT Next 3Y49.42%
EBIT Next 5Y23.17%
FCF growth 1Y30.91%
FCF growth 3Y-2.91%
FCF growth 5Y14.03%
OCF growth 1Y28.71%
OCF growth 3Y-2.14%
OCF growth 5Y13.49%

BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ

Can you provide the ChartMill fundamental rating for BRISTOL-MYERS SQUIBB CO?

ChartMill assigns a fundamental rating of 6 / 10 to 1BMY.MI.


What is the valuation status of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?

ChartMill assigns a valuation rating of 9 / 10 to BRISTOL-MYERS SQUIBB CO (1BMY.MI). This can be considered as Undervalued.


Can you provide the profitability details for BRISTOL-MYERS SQUIBB CO?

BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a profitability rating of 5 / 10.


What is the financial health of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?

The financial health rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 5 / 10.


How sustainable is the dividend of BRISTOL-MYERS SQUIBB CO (1BMY.MI) stock?

The dividend rating of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 8 / 10 and the dividend payout ratio is 82.81%.